Is Gujarat Themis Biosyn a Good Buy After Its Q1 FY27 Results?
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Market
Gujarat Themis Biosyn share price around Rs 418. 12.7% below 52-week high of Rs 479. Q1 FY27 revenue Rs 44 crore, up 21.5% YoY. PAT Rs 11 crore, up 22.2%. PE 115x.
Quick Answer
Gujarat Themis Biosyn’s Q1 FY27 results were strong, with revenue at Rs 44 crore and PAT climbing 22% to Rs 11 crore. The stock trades at a PE of 115x against an industry average near 51x, so some of this good news is already priced in. The Gujarat Themis Biosyn share price near Rs 418 reflects that optimism, so investors weighing whether Gujarat Themis Biosyn is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.
The Gujarat Themis Biosyn share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Gujarat Themis Biosyn is a manufacturer of active pharmaceutical ingredients (APIs), and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 44 crore, up 21.5% year on year, while profit after tax came in at Rs 11 crore, up 22.2% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Gujarat Themis Biosyn share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Gujarat Themis Biosyn share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Gujarat Themis Biosyn Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 44 crore | Rs 36 crore | 21.5% |
| EBITDA | Rs 21 crore | Rs 14 crore | 47.4% |
| Operating Margin | 47.8% | 39.6% | NA |
| Profit Before Tax | Rs 15 crore | Rs 12 crore | 25.2% |
| Net Profit / (Loss) | Rs 11 crore | Rs 9.06 crore | 22.2% |
Gujarat Themis Biosyn Q1 FY27 Performance Analysis
Check Gujarat Themis Biosyn Fundamentals on Univest Screener
Revenue growth of 21.5% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the active pharmaceutical ingredients (API) manufacturing sector.
The bigger story is on profitability. PAT grew 22% to Rs 11 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the Gujarat Themis Biosyn share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.
On a sequential basis, revenue moved down 2.7% sequentially from Rs 45 crore in the March 2026 quarter and net profit moved up 1.7% sequentially from Rs 11 crore in the prior quarter, giving a fuller picture of the trend behind the Gujarat Themis Biosyn share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Gujarat Themis Biosyn’s revenue grew 21.5% year on year this quarter, taking the quarterly base to Rs 44 crore in an active pharmaceutical ingredients (API) manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Gujarat Themis Biosyn share price.
Margin Movement
EBITDA rose 47.4% to Rs 21 crore, and operating margin moved to 47.8% from 39.6% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Gujarat Themis Biosyn’s debt-to-equity ratio stands at 0.56, a level worth monitoring given the quarter’s margin trend.
Valuation Context
The stock trades at a PE of 115.2x against an industry average of 51.2x, a premium that this quarter’s results will need to justify going forward.
Dividend Details
No interim dividend was declared alongside Gujarat Themis Biosyn’s Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.13%, based on dividends paid over the last year. Investors tracking the Gujarat Themis Biosyn share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Gujarat Themis Biosyn Share Price Outlook for FY27
The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Gujarat Themis Biosyn can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter’s momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.
For the Gujarat Themis Biosyn share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter’s pace, since any slowdown would put pressure on a stock priced for continued strength.
Gujarat Themis Biosyn Stock Performance
Download the Univest iOS App or Univest Android App to track Gujarat Themis Biosyn’s live share price and get daily stock updates.
The Gujarat Themis Biosyn share price was trading around Rs 418 as results season played out in late August 2026, roughly 12.7% below its 52-week high of Rs 479 and well above its 52-week low of Rs 225.
The Gujarat Themis Biosyn share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 16.22% and a book value of around Rs 80 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Valuation Risk
At 115.2x earnings against an industry average of 51.2x, the stock leaves little room for disappointment if growth slows.
Leverage Risk
A debt-to-equity ratio of 0.56 means the company’s earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer.
Sector and Demand Risk
As an active pharmaceutical ingredients (API) manufacturing business, Gujarat Themis Biosyn’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Gujarat Themis Biosyn share price well before the next result.
Conclusion
Gujarat Themis Biosyn’s Q1 FY27 results were genuinely strong, with revenue at Rs 44 crore and PAT up 22% to Rs 11 crore. That said, at a PE of 115.2x, the Gujarat Themis Biosyn share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Gujarat Themis Biosyn is a good buy should weigh the strong quarter against the valuation before adding at current levels.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Gujarat Themis Biosyn Q1 FY27 Results
What were Gujarat Themis Biosyn’s Q1 FY27 results?
Ans. Gujarat Themis Biosyn reported Q1 FY27 revenue of Rs 44 crore, up 21.5% year on year, and PAT of Rs 11 crore, up 22.2% year on year.
Is Gujarat Themis Biosyn a good buy after its Q1 FY27 results?
Ans. Gujarat Themis Biosyn’s core numbers improved this quarter, though at a PE of 115.2x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.
What is the Gujarat Themis Biosyn share price today?
Ans. The Gujarat Themis Biosyn share price was trading around Rs 418 in late August 2026, about 12.7% below its 52-week high of Rs 479 and well above its 52-week low of Rs 225.
What is Gujarat Themis Biosyn’s revenue and profit for Q1 FY27?
Ans. Gujarat Themis Biosyn reported revenue of Rs 44 crore and a net profit of Rs 11 crore for the quarter ended June 30, 2026.
Did Gujarat Themis Biosyn declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Gujarat Themis Biosyn’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Gujarat Themis Biosyn’s PE ratio and is it expensive?
Ans. The Gujarat Themis Biosyn share price trades at a trailing PE of 115.2x, against an industry average of 51.2x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Gujarat Themis Biosyn investors right now?
Ans. At 115.2x earnings against an industry average of 51.2x, the stock leaves little room for disappointment if growth slows. As an active pharmaceutical ingredients (API) manufacturing business, Gujarat Themis Biosyn’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Gujarat Themis Biosyn share price well before the next result.
What is Gujarat Themis Biosyn’s promoter shareholding?
Ans. Promoter shareholding data for Gujarat Themis Biosyn was not fully available for this quarter and should be checked on the company’s official filings.
